


## (R)-Irsenontrine

<b>Cat. No.:</b>	HY-132821B
<b>CAS No.:</b>	1429509-81-8
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>22</sub> N <sub>4</sub> O <sub>3</sub>
<b>Molecular Weight:</b>	390.44
<b>Target:</b>	Phosphodiesterase (PDE)
<b>Pathway:</b>	Metabolic Enzyme/Protease
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 25 mg/mL (64.03 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.5612 mL	12.8061 mL	25.6121 mL
	5 mM	0.5122 mL	2.5612 mL	5.1224 mL
	10 mM	0.2561 mL	1.2806 mL	2.5612 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

(R)-Irsenontrine ((R)-E2027), the R-enantiomer of [Irsenontrine](#) (HY-132821), is a potent phosphodiesterase 9 (PDE9) inhibitor with an IC<sub>50</sub> value of 0.041 μM. (R)-Irsenontrine can be used for the research of neurological diseases<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

PDE9  
0.041 μM (IC<sub>50</sub>)

### REFERENCES

[1]. Yoshihiko N, et, al. Pyrazoloquinoline derivative. WO2013051639A1.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA